Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YK012 in primary membranous nephropathy
NCT06982729Phase 1Recruiting
- Sponsor
- Excyte Biopharma Ltd
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of YK012 in primary membranous nephropathy (PMN) (2 arms), sponsored by Excyte Biopharma Ltd. Primary endpoints: Dose-limiting Toxicity at 28 days, Adverse Event at 77 weeks and 2 more. Started Mar 2025; status: recruiting.
02
Drugs
YK012
03
Conditions
primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT06982729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06982729.